Compare TRT & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRT | INO |
|---|---|---|
| Founded | 1958 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 109.1M | 100.4M |
| IPO Year | 1995 | 1999 |
| Metric | TRT | INO |
|---|---|---|
| Price | $10.39 | $1.27 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.75 |
| AVG Volume (30 Days) | 245.9K | ★ 6.2M |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.18 |
| EPS | ★ 0.02 | N/A |
| Revenue | $32,462,000.00 | ★ $42,220,086.00 |
| Revenue This Year | N/A | $20,156.19 |
| Revenue Next Year | N/A | $421.95 |
| P/E Ratio | $504.50 | ★ N/A |
| Revenue Growth | N/A | ★ 19.37 |
| 52 Week Low | $4.42 | $0.56 |
| 52 Week High | $21.38 | $2.86 |
| Indicator | TRT | INO |
|---|---|---|
| Relative Strength Index (RSI) | 44.39 | 66.01 |
| Support Level | $9.15 | $1.03 |
| Resistance Level | $12.01 | $1.79 |
| Average True Range (ATR) | 0.70 | 0.10 |
| MACD | -0.08 | 0.06 |
| Stochastic Oscillator | 10.44 | 94.23 |
Trio-Tech International is a provider of reliability test equipment and services to the semiconductor and other industries. Its customers are from automotive electronics, industrial electronics, computing and data storage, consumer electronics, and communication markets. The company operated its business in two segments: Semiconductor Back-end Solutions and Industrial Electronics. Geographically, the company operates in the United States (U.S), Singapore, Malaysia, Thailand and China.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.